The JAK2 mutation has become a diagnostic standard, and the level of allele burden is part of a usual diagnostic work up, although the World Health Organization (WHO) does not specify the reference value for setting the diagnosis of MPN [7]. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.